Page 379 - IJB-10-6

International Journal of Bioprinting 3D-printed NAFLD model

3. Parola M, Pinzani M. Liver fibrosis in NAFLD/NASH: coculturing hepatocytes, endothelial cells, and Kupffer cells.
from pathophysiology towards diagnostic and therapeutic Adv Healthc Mater. 2019;8(24):e1901379.
strategies. Mol Aspects Med. 2024;95:101231. doi: 10.1002/adhm.201901379
doi: 10.1016/j.mam.2023.101231
15. Cheng S, Yang Y, Zhou Y, Xiang W, Yao H, Ma L. Influence
4. Rosso C, Kazankov K, Younes R, et al. Crosstalk of different concentrations of uric acid on oxidative stress in
between adipose tissue insulin resistance and liver steatosis hepatocytes. Exp Ther Med. 2018;15(4):3659-3665.
macrophages in non-alcoholic fatty liver disease. J Hepatol. doi: 10.3892/etm.2018.5855
2019;71(5):1012-1021.
doi: 10.1016/j.jhep.2019.06.031 16. Michaut A, Le Guillou D, Moreau C, et al. A cellular model
to study drug-induced liver injury in nonalcoholic fatty
5. Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial liver disease: application to acetaminophen. Toxicol Appl
metabolites in obesity, NAFLD and T2DM. Nat Rev Pharmacol. 2016;292:40-55.
Endocrinol. 2019;15(5):261-273. doi: 10.1016/j.taap.2015.12.020
doi: 10.1038/s41574-019-0156-z
17. Luckert C, Braeuning A, de Sousa G, et al. Adverse outcome
6. Hendriks D, Brouwers JF, Hamer K, et al. Engineered pathway-driven analysis of liver steatosis in vitro: a case
human hepatocyte organoids enable CRISPR-based target study with cyproconazole. Chem Res Toxicol. 2018;31(8):
discovery and drug screening for steatosis. Nat Biotechnol. 784-798.
2023;41(11):1567-1581. doi: 10.1021/acs.chemrestox.8b00112
doi: 10.1038/s41587-023-01680-4
18. Kimura M, Iguchi T, Iwasawa K, et al. En masse organoid
7. Zhu C, Huai Q, Zhang X, Dai H, Li X, Wang H. Insights into phenotyping informs metabolic-associated genetic
the roles and pathomechanisms of ceramide and sphigosine- susceptibility to NASH. Cell. 2022;185(22):4216-4232 e16.
1-phosphate in nonalcoholic fatty liver disease. Int J Biol Sci. doi: 10.1016/j.cell.2022.09.031
2023;19(1):311.
doi: 10.7150/ijbs.78525 19. Yang H, Sun L, Pang Y, et al. Three-dimensional bioprinted
hepatorganoids prolong survival of mice with liver failure.
8. Im YR, Hunter H, de Gracia Hahn D, et al. A systematic Gut. 2021;70(3):567-574.
review of animal models of NAFLD finds high-fat, high-
fructose diets most closely resemble human NAFLD. doi: 10.1136/gutjnl-2019-319960
Hepatology. 2021;74(4):1884-1901. 20. Ryu JS, Lee M, Mun SJ, et al. Targeting CYP4A attenuates
doi: 10.1002/hep.31897 hepatic steatosis in a novel multicellular organotypic liver
model. J Biol Eng. 2019;13:69.
9. Smati S, Polizzi A, Fougerat A, et al. Integrative study of diet-
induced mouse models of NAFLD identifies PPARalpha as a doi: 10.1186/s13036-019-0198-8
sexually dimorphic drug target. Gut. 2022;71(4):807-821. 21. Leite SB, Roosens T, El Taghdouini A, et al. Novel human
doi: 10.1136/gutjnl-2020-323323 hepatic organoid model enables testing of drug-induced
10. Trépo E, Valenti L. Update on NAFLD genetics: from liver fibrosis in vitro. Biomaterials. 2016;78:1-10.
new variants to the clinic. J Hepatol. 2020;72(6): doi: 10.1016/j.biomaterials.2015.11.026
1196-1209. 22. Zhang B, Korolj A, Lai BFL, Radisic M. Advances in organ-
doi: 10.1016/j.jhep.2020.02.020 on-a-chip engineering. Nat Rev Mater. 2018;3(8):257-278.
11. Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- doi: 10.1038/ s41578-018-0034-7
and chemical-induced murine NASH model with rapid 23. Feaver RE, Cole BK, Lawson MJ, et al. Development of an
progression of steatohepatitis, fibrosis and liver cancer. in vitro human liver system for interrogating nonalcoholic
J Hepatol. 2018;69(2):385-395. steatohepatitis. JCI Insight. 2016;1(20):e90954.
doi: 10.1016/j.jhep.2018.03.011 doi: 10.1172/jci.insight.90954
12. Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. 24. Bulutoglu B, Rey-Bedón C, Kang YBA, Mert S, Yarmush ML,
Animal models for liver disease – a practical approach for Usta OB. A microfluidic patterned model of non-alcoholic
translational research. J Hepatol. 2020;73(2):423-440. fatty liver disease: applications to disease progression and
doi: 10.1016/j.jhep.2020.04.011 zonation. Lab Chip. 2019;19(18):3022-3031.
13. Ma L, Wu Y, Li Y, et al. Current advances on 3D‐bioprinted doi: 10.1039/c9lc00354a
liver tissue models. Adv Healthc Mater. 2020;9(24):2001517. 25. Lasli S, Kim HJ, Lee K, et al. A human liver-on-a-chip
doi: 10.1002/adhm.202001517
platform for modeling nonalcoholic fatty liver disease. Adv
14. Suurmond CE, Lasli S, van den Dolder FW, et al. In vitro Biosyst. 2019;3(8):e1900104.
human liver model of nonalcoholic steatohepatitis by doi: 10.1002/adbi.201900104

Volume 10 Issue 6 (2024) 371 doi: 10.36922/ijb.4312